CIB vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is critical, highlighted by a Piotroski F-Score of 0/9, indicating severe deterioration in financial fundamentals. While the stock has shown impressive long-term price appreciation and maintains a strong ROE of 16.96%, current growth metrics are catastrophic with YoY revenue down 80.10% and earnings down 72.30%. The stock is currently trading at $71.51, which is significantly above its growth-based intrinsic value of $55.30 and the analyst target price of $63.76. Despite an attractive dividend yield, the fundamental collapse outweighs the valuation appeal.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
CIB vs JPM: Head-to-Head Comparison
This page compares Grupo Cibest S.A. (CIB) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.